Literature DB >> 17934482

Aberrant cytokine signaling in leukemia.

R A Van Etten1.   

Abstract

Abnormalities of cytokine and growth factor signaling pathways are characteristic of all forms of leukemia: lymphoid and myeloid, acute and chronic. In normal hematopoietic cells, cytokines provide the stimulus for proliferation, survival, self-renewal, differentiation and functional activation. In leukemic cells, these pathways are usurped to subserve critical parts of the malignant program. In this review, our current knowledge of leukemic cell cytokine signaling will be summarized, and some speculations on the significance and implications of these insights will be advanced. A better understanding of aberrant cytokine signaling in leukemia should provide additional targets for the rational therapy of these diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934482      PMCID: PMC4344827          DOI: 10.1038/sj.onc.1210758

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  139 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  The Ras signaling pathway and the molecular basis of myeloid leukemogenesis.

Authors:  K Shannon
Journal:  Curr Opin Hematol       Date:  1995-07       Impact factor: 3.284

Review 3.  Cancer stem cells: lessons from leukemia.

Authors:  Jean C Y Wang; John E Dick
Journal:  Trends Cell Biol       Date:  2005-09       Impact factor: 20.808

4.  Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).

Authors:  Michaela Scherr; Anuhar Chaturvedi; Karin Battmer; Iris Dallmann; Beate Schultheis; Arnold Ganser; Matthias Eder
Journal:  Blood       Date:  2005-11-08       Impact factor: 22.113

5.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

6.  Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease.

Authors:  W Eisterer; X Jiang; O Christ; H Glimm; K H Lee; E Pang; K Lambie; G Shaw; T L Holyoake; A L Petzer; C Auewarakul; M J Barnett; C J Eaves; A C Eaves
Journal:  Leukemia       Date:  2005-03       Impact factor: 11.528

7.  Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.

Authors:  R M Weber-Nordt; C Egen; J Wehinger; W Ludwig; V Gouilleux-Gruart; R Mertelsmann; J Finke
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

8.  Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation.

Authors:  G Bhardwaj; B Murdoch; D Wu; D P Baker; K P Williams; K Chadwick; L E Ling; F N Karanu; M Bhatia
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

9.  FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome.

Authors:  S Xiao; S R Nalabolu; J C Aster; J Ma; L Abruzzo; E S Jaffe; R Stone; S M Weissman; T J Hudson; J A Fletcher
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

10.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Authors:  Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-X Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

View more
  41 in total

1.  Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.

Authors:  Katrin Friedbichler; Marc A Kerenyi; Boris Kovacic; Geqiang Li; Andrea Hoelbl; Saliha Yahiaoui; Veronika Sexl; Ernst W Müllner; Sabine Fajmann; Sabine Cerny-Reiterer; Peter Valent; Hartmut Beug; Fabrice Gouilleux; Kevin D Bunting; Richard Moriggl
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

2.  Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth.

Authors:  Chen Chen; Xin Wei; Xiaoquan Rao; Jun Wu; Shenglan Yang; Fuqiong Chen; Ding Ma; Jianfeng Zhou; Ryan T Dackor; Darryl C Zeldin; Dao Wen Wang
Journal:  J Pharmacol Exp Ther       Date:  2010-10-28       Impact factor: 4.030

3.  Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.

Authors:  Steven M Kornblau; David McCue; Neera Singh; Wenjing Chen; Zeev Estrov; Kevin R Coombes
Journal:  Blood       Date:  2010-08-02       Impact factor: 22.113

4.  Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary hematopoietic malignancies.

Authors:  Abhisek Mitra; Jeremy A Ross; Georgialina Rodriguez; Zsuzsanna S Nagy; Harry L Wilson; Robert A Kirken
Journal:  J Biol Chem       Date:  2012-03-22       Impact factor: 5.157

5.  The prognostic significance of serum and cerebrospinal fluid MMP-9, CCL2 and sVCAM-1 in leukemia CNS metastasis.

Authors:  Meng-Ya Si; Zhi-Cheng Fan; Ya-Zhen Li; Xiao-Lan Chang; Qing-Dong Xie; Xiao-Yang Jiao
Journal:  J Neurooncol       Date:  2015-01-30       Impact factor: 4.130

6.  Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.

Authors:  Hongfeng Yuan; Zhiqiang Wang; Ling Li; Hao Zhang; Hardik Modi; David Horne; Ravi Bhatia; WenYong Chen
Journal:  Blood       Date:  2011-12-29       Impact factor: 22.113

7.  High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  George S Laszlo; Rhonda E Ries; Chelsea J Gudgeon; Kimberly H Harrington; Todd A Alonzo; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Soheil Meshinchi; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2014-03-24

Review 8.  Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.

Authors:  Lothar Hennighausen; Gertraud W Robinson
Journal:  Genes Dev       Date:  2008-03-15       Impact factor: 11.361

9.  Distinct gene-expression profiles characterize mammary tumors developed in transgenic mice expressing constitutively active and C-terminally truncated variants of STAT5.

Authors:  Tali Eilon; Itamar Barash
Journal:  BMC Genomics       Date:  2009-05-18       Impact factor: 3.969

10.  Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses.

Authors:  Lina Han; Albertus T J Wierenga; Marjan Rozenveld-Geugien; Kim van de Lande; Edo Vellenga; Jan Jacob Schuringa
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.